Success Metrics

Clinical Success Rate
60.0%

Based on 6 completed trials

Completion Rate
60%(6/10)
Active Trials
0(0%)
Results Posted
167%(10 trials)
Terminated
4(40%)

Phase Distribution

Ph phase_2
5
50%
Ph phase_3
2
20%
Ph phase_1
3
30%

Phase Distribution

3

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
3(30.0%)
Phase 2Efficacy & side effects
5(50.0%)
Phase 3Large-scale testing
2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

60.0%

6 of 10 finished

Non-Completion Rate

40.0%

4 ended early

Currently Active

0

trials recruiting

Total Trials

10

all time

Status Distribution
Completed(6)
Terminated(4)

Detailed Status

Completed6
Terminated4

Development Timeline

Analytics

Development Status

Total Trials
10
Active
0
Success Rate
60.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (30.0%)
Phase 25 (50.0%)
Phase 32 (20.0%)

Trials by Status

completed660%
terminated440%

Recent Activity

0 active trials
Showing 5 of 10
completedphase_2

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

NCT00537017
terminatedphase_1

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

NCT03099161
terminatedphase_2

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

NCT00686699
completedphase_2

Dyskinesia in Parkinson's Disease (Study P04501)

NCT00406029
completedphase_2

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

NCT01294800
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT00537017Phase 2

Follow Up Safety Study of SCH 420814 in Subjects With Parkinson's Disease (P05175)

Completed
NCT03099161Phase 1

Study of Preladenant (MK-3814) Alone and With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3814A-062)

Terminated
NCT00686699Phase 2

Study of Preladenant for the Treatment of Antipsychotic Induced Movement Disorders in Participants With Schizophrenia (Study P04628)

Terminated
NCT00406029Phase 2

Dyskinesia in Parkinson's Disease (Study P04501)

Completed
NCT01294800Phase 2

A Dose Finding Study of Preladenant (SCH 420814) for the Treatment of Parkinson's Disease (PD) in Japanese Patients (P06402)

Completed
NCT00693472Phase 2

Study of Preladenant for the Treatment of Neuroleptic Induced Akathisia (Study P05145)

Terminated
NCT01215227Phase 3

An Active-Controlled Extension Study to NCT01155466 [P04938] and NCT01227265 [P07037] (P06153)

Terminated
NCT01323855Phase 1

A Study to Assess Pharmacokinetics (PK) of Preladenant in Participants With Chronic Renal Impairment (CRI) (P06512)

Completed
NCT01227265Phase 3

Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)

Completed
NCT01465412Phase 1

A Study to Assess Pharmacokinetics of Preladenant in Participants With Chronic Hepatic Impairment (P06513)

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10